NCT04611789

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

A Randomized, Placebo-Controlled, Participant- and Investigator-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of LY3832479 Administered Subcutaneously to Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3832479	Administered subcutaneously
DRUG	Placebo	Administered subcutaneously

Timeline

• Start date: 2020-11-02
• Primary completion: 2021-02-10
• Completion: 2021-02-10
• First posted: 2020-11-02
• Last updated: 2021-12-06
• Results posted: 2021-12-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study